Puma Biotechnology Reports $56.5 Million Revenue for Q2 2026, Net Income Increases to $8.2 Million

Puma Biotechnology, Inc. reported a total revenue of approximately $56.5 million for the three months ended June 30, 2026, marking an increase from $52.4 million in the same period last year. This growth was primarily driven by a 12.3% rise in product revenue, netting approximately $53.6 million, compared to $49.2 million in the prior year. However, royalty revenue decreased to $2.9 million from $3.2 million, attributed to lower sales by international partners. For the six months ended June 30, 2026, total revenue reached approximately $101.3 million, up from $98.4 million, with product revenue also increasing to $95.5 million from $92.3 million.

Operating expenses for the second quarter of 2026 totaled approximately $48.9 million, compared to $45.8 million in the same quarter of 2025. The increase was driven by higher research and development costs, which rose to $18.9 million from $15.5 million, reflecting increased clinical trial activities, particularly for alisertib. Selling, general, and administrative expenses decreased slightly to $17.5 million from $18.0 million, primarily due to reduced payroll costs and a reversal of a legal accrual related to litigation. The company reported a net income of $8.2 million for the second quarter, up from $5.9 million in the prior year.

Puma's balance sheet as of June 30, 2026, showed total assets of $192.7 million, down from $216.3 million at the end of 2025. Cash and cash equivalents increased to $36.5 million from $29.6 million, while marketable securities decreased to $57.4 million from $67.9 million. The company’s stockholders’ equity rose to $138.5 million, compared to $130.3 million at the end of the previous year. Notably, Puma fully repaid its outstanding debt of $102 million under the Athyrium Note Purchase Agreement ahead of its maturity date, which significantly improved its financial position.

Strategically, Puma continues to focus on the commercialization of NERLYNX, which is approved in over 60 countries outside the U.S. The company is also advancing its development of alisertib, having initiated clinical trials for its use in small cell lung cancer and hormone receptor-positive breast cancer. As of June 30, 2026, Puma employed approximately 38 sales specialists in the U.S. and plans to expand its market presence through exclusive sub-license agreements in various international territories.

Looking ahead, Puma anticipates continued investment in research and development, particularly for alisertib, and expects to rely on its existing cash reserves and future product sales to fund its operations. The company acknowledges the potential for significant future losses and emphasizes the need for ongoing revenue generation to sustain its business model.